A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, dose escalation study to evaluate the safety and
tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily
subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.